Fig. 1: Patient journey while receiving anticancer therapies.

Prior to administration of nephrotoxic anticancer therapies, all patients should undergo a Kidney Health Assessment. The Kidney Health Assessment is a personalized evaluation of the kidney health of the patient and their potential risk of acute kidney disease (AKD) if exposed to the planned anticancer therapy. The Kidney Health Assessment is followed by a personalized Kidney Health Response, which is a risk mitigation and monitoring plan aimed at minimizing AKD risk, mitigating and/or managing AKD complications, avoiding further injuries, managing comorbid conditions impacted by AKD and facilitating rapid recovery.